门冬胰岛素30治疗2型糖尿病的疗效观察

The effects of insulin aspart 30 injection in the treatment of type 2 diabetes

目的比较门冬胰岛素30(诺和锐30特充)和预混人胰岛素(诺和灵30R)每日2次在开始胰岛素治疗的2型糖尿病(T2DM)患者的疗效和安全性。方法48例口服药物治疗血糖控制不佳的T2DM患者被随机分为诺和锐30特充治疗组和诺和灵30R治疗组,采用每日早、晚餐前两次皮下注射方案,观察两组患者5个时点血糖、低血糖事件及血糖达标时间、最后每日胰岛素用量、患者依从性差异。结果诺和锐30特充治疗组空腹及三餐后2 h、夜间血糖水平和诺和灵30R组相比差异无统计学意义(P>0.05);诺和锐30特充组低血糖、严重低血糖发生次数、每日胰岛素用量低于诺和灵30R组(P<0.05);诺和锐30特充组患者依从性高于诺和灵30R组(P<0.05)。结论诺和锐30特充治疗2型糖尿病和诺和灵30R控制血糖同样有效,但安全性和患者依从性较高。

Objective To compare the efficacy and safety of BIAsp30 and BHI30 in patients with type 2 diabetes mellitus （T2DM）who begin to use insulin in a twice-daily injection. Methods Forty-eight cases who had inadequate glycemia control by sulfonylurea and/or other oral agents were randomly divided into two groups using twice-daily insulin for 10-days BIAsp30 and BHI30. Blood glucose at 5 time points ,hypoglycemia,the time up to the standard of blood glucose, dosage of insulin per day and patient compliance were observed. Efficacy was assessed by analysis of variance of two-group data. Results The Efficacy was not significantly between two groups （P 〉 0.05 ） ; The frequency of hypoglycemia ,dosage of insulin per day was lower in BIAsp30 group than those in the BHI30 group（ P 〈 0.05 ）, and the patient compliance was higher in BIAsp30 group than that in the other one （ P 〈 0.05 ）. Conclusion BIAsp30 is superior to BHI30, not in safety but also in patient compliance , and the total blood glucose control shows similar in both treatments.